Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation

European Journal of Medicinal Chemistry

Volumn 95, Issue , 2015, Pages 29-34

  Munoz, Lenka ^a   Kavanagh, Madeline E ^b   Phoa, Athena F ^a   Heng, Benjamin ^c   Dzamko, Nicolas ^d,e   Chen, Ew Jun ^a   Doddareddy, Munikumar Reddy ^a   Guillemin, Gilles J ^c   Kassiou, Michael ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

LRRK2 inhibitors; Neuroinflammation; Structureeactivity relationships

Indexed keywords

ANTIINFLAMMATORY AGENT; INTERLEUKIN 6; LEUCINE RICH REPEAT KINASE 2 INHIBITOR; LEUCINE RICH REPEAT KINASE 2 INHIBITOR G2019S; LEUCINE RICH REPEAT KINASE 2 INHIBITOR N1; LIPOPOLYSACCHARIDE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE; INTERLEUKIN 1BETA; LRRK2 PROTEIN, HUMAN; LRRK2-IN1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIMIDINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ASSAY; COMPUTER MODEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SYNTHESIS; EC50; GLIOMA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MICROGLIA; MOLECULAR DOCKING; NERVOUS SYSTEM INFLAMMATION; PHYSICAL CHEMISTRY; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; GLIOMA; INFLAMMATION; PATHOLOGY; SECRETION (PROCESS);

ANTI-INFLAMMATORY AGENTS; BENZODIAZEPINONES; CELLS, CULTURED; GLIOMA; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MICROGLIA; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES;

EID: 84924757163     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1038/onc.2014.225     Document Type: Article

References (25)

1. M. Funayama K. Hasegawa H. Kowa M. Saito S. Tsuji F. Obata A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1 Ann. Neurol. 51 2002 296 301
2. C.Y. Chen Y.H. Weng K.Y. Chien K.J. Lin T.H. Yeh Y.P. Cheng C.S. Lu H.L. Wang (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD Cell. Death Differ. 19 2012 1623 1633
3. M. Devine H. Plun-Favreau N. Wood Parkinson's disease and cancer: two wars, one front Nat. Rev. Cancer 11 2011 812 823
4. M. Lichtenberg A. Mansilla V.R. Zecchini A. Fleming D.C. Rubinsztein The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity Cell. Death Dis. 2 2011 e196
5. B.D. Lee V.L. Dawson T.M. Dawson Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease Trends Pharmacol. Sci. 33 2012 365 373
6. M.S. Moehle P.J. Webber T. Tse N. Sukar D.G. Standaert T.M. DeSilva R.M. Cowell A.B. West LRRK2 inhibition attenuates microglial inflammatory responses J. Neurosci. 32 2012 1602 1611
7. N. Dzamko F. Inesta-Vaquera J. Zhang C. Xie H. Cai S. Arthur L. Tan H. Choi N. Gray P. Cohen P. Pedrioli K. Clark D.R. Alessi The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling PLoS One 7 2012 e39132
8. B. Kim M.-S. Yang D. Choi J.-H. Kim H.-S. Kim W. Seol S. Choi I. Jou E.-Y. Kim E.-H. Joe Impaired inflammatory responses in murine LRRK2-knockdown brain microglia PLoS One 7 2012 e34693
9. N. Dzamko G. Halliday An emerging role for LRRK2 in the immune system Biochem. Soc. Trans. 40 2012 1134 1139
10. L. Munoz A.J. Ammit Targeting p38 MAPK pathway for the treatment of Alzheimer's disease Neuropharmacology 58 2010 561 568
11. A.K. Walker A. Kavelaars C.J. Heijnen R. Dantzer Neuroinflammation and comorbidity of pain and depression Pharmacol. Rev. 66 2014 80 101
12. E. Ellwardt F. Zipp Molecular mechanisms linking neuroinflammation and neurodegeneration in MS Exp. Neurol. 2014
13. B. Lee J.-H. Shin J. VanKampen L. Petrucelli A. West H. Ko Y.-I. Lee K. Maguire-Zeiss W. Bowers H. Federoff V. Dawson T. Dawson Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease Nat. Med. 16 2010 998 1000
14. J. Nichols N. Dzamko J. Hutti L. Cantley M. Deak J. Moran P. Bamborough A.D. Reith D.R. Alessi Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease Biochem. J. 424 2009 47 60
15. M.E. Kavanagh M.R. Doddareddy M. Kassiou The development of CNS-active LRRK2 inhibitors using property-directed optimisation Bioorg Med. Chem. Lett. 23 2013 3690 3696
16. A.A. Estrada X. Liu C. Baker-Glenn A. Beresford D.J. Burdick M. Chambers B.K. Chan H. Chen X. Ding A.G. DiPasquale S.L. Dominguez J. Dotson J. Drummond M. Flagella S. Flynn R. Fuji A. Gill J. Gunzner-Toste S.F. Harris T.P. Heffron T. Kleinheinz D.W. Lee C.E. Le Pichon J.P. Lyssikatos A.D. Medhurst J.G. Moffat S. Mukund K. Nash K. Scearce-Levie Z. Sheng D.G. Shore T. Tran N. Trivedi S. Wang S. Zhang X. Zhang G. Zhao H. Zhu Z.K. Sweeney Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors J. Med. Chem. 55 2012 9416 9433
17. X. Deng N. Dzamko A. Prescott P. Davies Q. Liu Q. Yang J. Lee M. Patricelli T. Nomanbhoy D. Alessi N. Gray Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat. Chem. Biol. 7 2011 203 205
18. X. Zhu J. Kim J. Newcomb P. Rose D. Stover L. Toledo H. Zhao K. Morgenstern Structural analysis of lymphocyte-specific kinase Lck in complex with non-selective and Src family selective inhibitors Structure 7 1999 651 661
19. T. Reekie M.E. Kavanagh M. Longworth M. Kassiou Synthesis of biologically active seven-membered-ring heterocycles Synthesis 45 2013 3211 3227
20. Y. Yeung N. Bryce S. Adams N. Braidy M. Konayagi K. McDonald C. Teo G. Guillemin T. Grewal L. Munoz p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and invasiveness of human U251 glioblastoma cells J. Neurooncol. 109 2012 35 44
21. F. Gurgis Y.T. Yeung M. Tang B. Heng M. Buckland A. Ammit J. Haapasalo H. Haapasalo G. Guillemin T. Grewal L. Munoz The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1Î 2 driven IL-6 secretion in glioblastoma cells Oncogene 2014
22. C.J. Gloeckner A. Schumacher K. Boldt M. Ueffing The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro J. Neurochem. 109 2009 959 968
23. L.M. Collins A. Toulouse T.J. Connor Y.M. Nolan Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease Neuropharmacology 62 2012 2154 2168
24. D.C. Swinney J. Anthony How were medicines discovered? Nat. Rev. Drug Disc. 10 2011 507 519
25. D. Kommi D. Kumar R. Bansal R. Chebolu A. Chakraborti. All-waterg chemistry of tandem N-alkylation-reduction-condensation for synthesis of N-arylmethyl-2-substituted benzimidazoles Green Chem. 14 2012 3329 3335